Mark S Sulkowski
Overview
Explore the profile of Mark S Sulkowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
196
Citations
9864
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Alqahtani S, Sulkowski M
Med Clin North Am
. 2023 Mar;
107(3):423-433.
PMID: 37001945
Hepatitis C virus (HCV) infection contributes significantly to liver cirrhosis and hepatocellular carcinoma (HCC), often requiring liver transplantation. Introducing direct-acting antiviral agents (DAAs) has radically changed HCV treatment. DAAs achieve...
12.
Sulkowski M
J Viral Hepat
. 2023 Mar;
30 Suppl 1:39-42.
PMID: 36856472
This article discusses the impact of Hepatitis D virus (HDV) infection as a major cause of liver-related morbidity and mortality in people with Hepatitis B virus (HBV) infection. The article...
13.
Sachithanandham J, Balagopal A, Leep-Lazar J, Quinn J, Bowden K, Ward K, et al.
J Infect Dis
. 2023 Feb;
228(3):311-320.
PMID: 36722133
Background: Mathematical models explain how antivirals control viral infections. Hepatitis C virus (HCV) treatment results in at least 2 phases of decline in viremia. The first phase reflects clearance of...
14.
Hyde Z, Roura R, Signer D, Patel A, Cohen J, Saheed M, et al.
J Viral Hepat
. 2022 Nov;
30(2):129-137.
PMID: 36441638
There is a significant number of Emergency Department (ED) patients with known chronic hepatitis C virus (HCV) infection who have not been treated with directly acting antivirals. We implemented a...
15.
Grudda T, Hwang H, Taddese M, Quinn J, Sulkowski M, Sterling R, et al.
J Clin Invest
. 2022 Jul;
132(18).
PMID: 35797115
The focus of hepatitis B functional cure, defined as sustained loss of hepatitis B virus (HBV) surface antigen (HBsAg) and HBV DNA from blood, is on eliminating or silencing the...
16.
Sulkowski M, Agarwal K, Ma X, Nguyen T, Schiff E, Hann H, et al.
J Hepatol
. 2022 Jun;
77(5):1265-1275.
PMID: 35697332
Background & Aims: Nucleos(t)ide reverse transcriptase inhibitors do not completely suppress HBV DNA in chronic HBV infection (cHBV). Vebicorvir (VBR) is an investigational core inhibitor that interferes with multiple aspects...
17.
Yuen M, Agarwal K, Ma X, Nguyen T, Schiff E, Hann H, et al.
J Hepatol
. 2022 Apr;
77(3):642-652.
PMID: 35460726
Background & Aims: HBV nucleos(t)ide reverse transcriptase inhibitors (NrtIs) do not completely suppress HBV replication. Previous reports indicate persistent viremia during NrtI treatment despite HBV DNA being undetectable. HBV core...
18.
Sulkowski M
Gastroenterol Hepatol (N Y)
. 2021 Dec;
17(5):230-232.
PMID: 34924891
No abstract available.
19.
Reau N, Sulkowski M, Thomas E, Sundaram V, Xu Q, Cheng W, et al.
Adv Ther
. 2021 Oct;
38(12):5777-5790.
PMID: 34704194
Introduction: Hepatitis C virus (HCV) is the most common bloodborne chronic infection in the US. Following approval of highly effective, direct-acting antivirals in 2014, the diagnostic and treatment rates for...
20.
Weld E, Astemborski J, Kirk G, Sulkowski M, Katz S, Rothman R, et al.
Clin Infect Dis
. 2021 Oct;
75(1):3-10.
PMID: 34699587
Background: Whereas safe, curative treatments for hepatitis C virus (HCV) have been available since 2015, there are still 58 million infected persons worldwide, and global elimination may require new paradigms....